Clinical Trials Feasibility Risk Assessment and Planning for Success - A Depression Case Study

Clinical Trials Feasibility Risk Assessment and Planning for Success - A Depression Case Study
Summary

This report provides the global clinical trial landscape for depression and identifies key analysis of the main features in order to run similar trials successfully.

As the prevalence of depression has increased, the outlook of it has also changed in positive ways. Better support and services for depression as well as the increase of discussing this order has lead to an increase of depression clinical trials. The COVID-19 pandemic has played a major role in that.

Key HighlightsCOVID-19 pandemic has changed the landscape of depression clinical trialsDepression clinical trials are being ran all around the world, with North America having the most.Top sponsors for depression trials are Eli Lilly and Massachusetts General Hospital.The important of eliminating delays in depression clinical trials.It is essential to select the right trial design, such as sites and investigators.ScopeThis report provides a review of global depression clinical trials derived from the GlobalData’s Clinical Trials Database and Feasibility Planner. The aim of this report is to provide analyses of these trials, coupled with analyses of what to expect when running a similar trial.Reasons to BuyIdentifies and analyses depression clinical trials by multiple trial designs, such as trial start year, phase and virtual components.Examines the effect of COVID-19 on depression trialsGives reason for certain trends seen in depression trialsUses the GlobalData's Feasibility Planner to help to improve trial planningComparison of enrollment parameters for different trials to an industry averageProvides analysis of best suited clinical trial sites and investigators for depression trials